Market revenue in 2024 | USD 1,483.6 million |
Market revenue in 2030 | USD 1,614.4 million |
Growth rate | 1.4% (CAGR from 2025 to 2030) |
Largest segment | Conventional |
Fastest growing segment | Molecular |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Molecular, Conventional |
Key market players worldwide | BioMerieux SA, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG ADR, Becton Dickinson & Co, Qiagen NV, Thermo Fisher Scientific Inc, Meridian Bioscience, Hologic, Inc. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hospital acquired infections diagnostics market will help companies and investors design strategic landscapes.
Conventional was the largest segment with a revenue share of 54% in 2024. Horizon Databook has segmented the Europe hospital acquired infections diagnostics market based on molecular, conventional covering the revenue growth of each sub-segment from 2018 to 2030.
The market is driven by the high disease burden, the availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and the presence of major players.
According to an article from the National Center for Biotechnology Information (NCBI), the major subtype of healthcare-associated diseases is urinary tract infections (HTIs). According to the European Centre for Disease Control (ECDC), 4.3 million patients in the European Union/European Economic Area (EU/EEA) are affected by healthcare-associated infections (HAIs) each year.
This data comes from the ECDC's 2022–2023-point prevalence survey, Further, in June 2024, QIAGEN launched 35 new digital PCR assays for microbial applications, enhancing detection of pathogens causing tropical diseases, STIs, and UTIs, expanding its portfolio to over 680 targets for improved infectious disease research.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe hospital acquired infections diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe hospital acquired infections diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account